Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:      
Research and development, including stock-based compensation of $469,357, $626,002 and $451,334, respectively $ 22,613,968 $ 18,057,025 $ 22,416,651
General and administrative, including stock-based compensation of $977,192, $929,521 and $1,171,794, respectively 11,625,621 9,809,423 8,707,774
Total operating expenses 34,239,589 27,866,448 31,124,425
Loss from operations (34,239,589) (27,866,448) (31,124,425)
Other income (expense):      
Interest income 192,702 359,270 672,227
Other expense (2,165,044)    
Change in fair value of warrant liabilities 8,056,258 14,712,685 (7,232,226)
Total other income (expense) 6,083,916 15,071,955 (6,559,999)
Net loss $ (28,155,673) $ (12,794,493) $ (37,684,424)
Per share information:      
Net loss per share of common stock, basic and diluted $ (1.24) $ (1.54) $ (4.95)
Basic and diluted weighted average shares outstanding 22,763,528 8,283,509 7,606,266